Michael H. Davidson, CEO of NewAmsterdam Pharma Co N.V. ($NAMS), made ten open market sales of common shares in the last 365 days, totaling $25.3 million. His most recent sale occurred on March 2, 2026. These $NAMS insider sales rank 557th among 11,678 individuals in our database by total value sold, surpassing the average of $8.6 million and 6.4 transactions per insider. He reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | M | Option (right to buy) | 443707 | $0.00 | 239,267.0000 | 119,000,266 | 64.97% | 0.37% |
| March 2, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | S | Ordinary Shares | 443707 | $33.25 | 174,144.0000 | 119,000,266 | 71.81% | 0.37% |
| March 2, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | M | Ordinary Shares | 443707 | $0.00 | 617,851.0000 | 119,000,266 | 254.79% | 0.37% |
| Feb. 24, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | M | Option (right to buy) | 64708 | $0.00 | 924,559.0000 | 119,000,266 | 6.54% | 0.05% |
| Feb. 26, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | S | Ordinary Shares | 17924 | $34.44 | 459,859.0000 | 119,000,266 | 3.75% | 0.02% |
| Feb. 26, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | S | Ordinary Shares | 165408 | $33.63 | 763,498.0000 | 119,000,266 | 17.81% | 0.14% |
| Feb. 26, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | M | Ordinary Shares | 183332 | $0.00 | 928,906.0000 | 119,000,266 | 24.59% | 0.15% |
| Feb. 25, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | S | Ordinary Shares | 1300 | $36.68 | 745,574.0000 | 119,000,266 | 0.17% | 0.00% |
| Feb. 25, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | S | Ordinary Shares | 10436 | $35.96 | 746,874.0000 | 119,000,266 | 1.38% | 0.01% |
| Feb. 25, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | S | Ordinary Shares | 46517 | $35.11 | 757,310.0000 | 119,000,266 | 5.79% | 0.04% |
| Feb. 25, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | M | Ordinary Shares | 58253 | $0.00 | 803,827.0000 | 119,000,266 | 7.81% | 0.05% |
| Feb. 24, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | S | Ordinary Shares | 3161 | $36.46 | 745,574.0000 | 119,000,266 | 0.42% | 0.00% |
| Feb. 24, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | S | Ordinary Shares | 61547 | $36.13 | 748,735.0000 | 119,000,266 | 7.60% | 0.05% |
| Feb. 24, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | M | Ordinary Shares | 64708 | $0.00 | 810,282.0000 | 119,000,266 | 8.68% | 0.05% |
| Feb. 26, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | M | Option (right to buy) | 183332 | $0.00 | 682,974.0000 | 119,000,266 | 21.16% | 0.15% |
| Feb. 25, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | M | Option (right to buy) | 58253 | $0.00 | 866,306.0000 | 119,000,266 | 6.30% | 0.05% |
| Jan. 9, 2026 | TENAX THERAPEUTICS, INC. | $TENX | Davidson Michael H. | Director | A | Stock Option (right to buy) | 30000 | $0.00 | 210,008.0000 | 39,741,404 | 16.67% | 0.08% |
| Jan. 7, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | S | Ordinary Shares | 11582 | $0.00 | 378,859.0000 | 119,000,266 | 2.97% | 0.01% |
| Jan. 7, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | A | Ordinary Shares | 81000 | $0.00 | 459,859.0000 | 119,000,266 | 21.38% | 0.07% |
| Jan. 7, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | A | Option (right to buy) | 364000 | $0.00 | 364,000.0000 | 119,000,266 | 9999.99% | 0.31% |
| July 1, 2025 | TENAX THERAPEUTICS, INC. | $TENX | Davidson Michael H. | Not found | A | Stock Option (right to buy) | 80000 | $0.00 | 180,008.0000 | 15,271,705 | 79.99% | 0.52% |
| June 5, 2025 | BioAge Labs, Inc. | $BIOA | Davidson Michael H. | Not found | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 35,850,037 | 9999.99% | 0.06% |
| March 26, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | M | Ordinary Shares | 38394 | $0.00 | 402,699.0000 | 94,358,067 | 10.54% | 0.04% |
| March 26, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | A | Restricted Stock Unit | 38394 | $0.00 | 38,394.0000 | 94,358,067 | 9999.99% | 0.04% |
| March 26, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | M | Restricted Stock Unit | 38394 | $0.00 | 0.0000 | 94,358,067 | 100.00% | 0.04% |
| March 26, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | S | Ordinary Shares | 12258 | $0.00 | 390,441.0000 | 94,358,067 | 3.04% | 0.01% |
| March 26, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | A | Ordinary Shares | 30992 | $0.00 | 364,305.0000 | 94,358,067 | 9.30% | 0.03% |
| Jan. 6, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | A | Option (right to buy) | 670467 | $0.00 | 670,467.0000 | 94,358,067 | 9999.99% | 0.71% |
| Jan. 7, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | A | Ordinary Shares | 123529 | $0.00 | 123,529.0000 | 94,358,067 | 9999.99% | 0.13% |
| Jan. 2, 2025 | Silence Therapeutics plc | $SLN | Davidson Michael H. | Not found | A | Share Option (Right to Buy) | 48000 | $0.00 | 48,000.0000 | 138,752,224 | 9999.99% | 0.03% |
| Dec. 10, 2024 | TENAX THERAPEUTICS, INC. | $TENX | Davidson Michael H. | Not found | A | Stock Option (right to buy) | 100000 | $0.00 | 100,008.0000 | 21,161,143 | 9999.99% | 0.47% |
| Oct. 9, 2024 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | G | Warrant (right to buy) | 15000 | $11.50 | 85,000.0000 | 94,754,140 | 15.00% | 0.02% |
| Sept. 25, 2024 | BioAge Labs, Inc. | $BIOA | Davidson Michael H. | Not found | A | Stock Option (Right to Buy) | 15000 | $0.00 | 15,000.0000 | 0 | 9999.99% | 0.00% |
| March 26, 2024 | BioAge Labs, Inc. | $BIOA | Davidson Michael H. | Not found | A | Stock Option (Right to Buy) | 33986 | $0.00 | 33,986.0000 | 0 | 9999.99% | 0.00% |
| Aug. 20, 2024 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | P | Ordinary Shares | 5000 | $16.27 | 818,563.0000 | 82,161,956 | 0.61% | 0.01% |
| Aug. 8, 2024 | TENAX THERAPEUTICS, INC. | $TENX | Davidson Michael H. | Not found | P | Common Stock | 2500 | $0.00 | 2,881.0000 | 248,447 | 656.17% | 1.01% |
| Aug. 8, 2024 | TENAX THERAPEUTICS, INC. | $TENX | Davidson Michael H. | Not found | P | Warrant | 25000 | $0.00 | 25,000.0000 | 248,447 | 9999.99% | 10.06% |
| Aug. 8, 2024 | TENAX THERAPEUTICS, INC. | $TENX | Davidson Michael H. | Not found | P | Pre-Funded Warrant | 47500 | $0.00 | 47,500.0000 | 248,447 | 9999.99% | 19.12% |
| June 20, 2024 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | P | Ordinary Shares | 5000 | $17.26 | 813,563.0000 | 82,161,956 | 0.62% | 0.01% |
| Jan. 1, 2024 | NewAmsterdam Pharma Co N.V. | $NAMS | Davidson Michael H. | Chief Executive Officer | A | Option (right to buy) | 1039939 | $0.00 | 1,039,939.0000 | 82,161,956 | 9999.99% | 1.27% |